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Background:Human serumMUC1 peptide fragments bearing aberrantO-glycans are secreted from columnar ep-
ithelial cell surfaces and known as clinically important serum biomarkers for the epithelial carcinoma when a
speciﬁcmonoclonal antibody can probe disease-relevant epitopes. Despite the growing importance ofMUC1 gly-
copeptides as biomarkers, the precise epitopes of most anti-MUC1 monoclonal antibodies remains unclear.
Methods: A novel protocol for the fabrication of versatile microarray displaying peptide/glycopeptide library was
investigated for the construction of highly sensitive and accurate epitope mapping assay of various anti-MUC1
antibodies.
Results: Selective imine-coupling between aminooxy-functionalized methacrylic copolymer with phos-
phorylcholine unit and synthetic MUC1 glycopeptides-capped by a ketone linker at N-terminus provided a facile
and seamless protocol for the preparation of glycopeptides microarray platform. It was demonstrated that
anti-KL-6 monoclonal antibody shows an extremely speciﬁc and strong binding afﬁnity toward MUC1 frag-
ments carrying sialyl T antigen (Neu5Acα2,3Galβ1,3GalNAcα1→) at Pro-Asp-Thr-Arg motif when com-
pared with other seven anti-MUC1 monoclonal antibodies such as VU-3D1, VU-12E1, VU-11E2, Ma552, VU-
3C6, SM3, and DF3. The present microarray also uncovered the occurrence of IgG autoantibodies in healthy
human sera that bind speciﬁcally with sialyl T antigen attached at ﬁve potential O-glycosylation sites of MUC1
tandem repeats.
Conclusion: We established a straightforward strategy toward the standardized microarray platform allowing
highly sensitive and accurate epitope mapping analysis by reducing the background noise due to nonspeciﬁc
protein adsorption.
General signiﬁcance: The present approach would greatly accelerate the discovery research of new class autoan-
tibodies as well as the development of therapeutic mAbs reacting speciﬁcally with disease-relevant epitopes.© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
MUC1 glycoprotein [1] is highly overexpressed in over 90% of breast
cancer [2,3] and many other cancers such as prostate cancer, hepatocel-
lular carcinoma, pancreatic cancer, colon cancer, or ovarian carcinoma
[4,5]. In addition, the expression level of the abnormal and immuno-
genic truncated glycoforms such as GalNAcα1 → (Tn antigen),
Galα1,3GalNAcα1 → (T or TF antigen, core 1 type disaccharide),
Neu5Acα2,6GalNAcα1 → (STn antigen) are considered to increase
according to up- or down-regulation of some glycosyltransferases.
Owing mainly to the differences in such glycan structures at ﬁve po-
tential glycosylation sites, antigenic structures (epitopes) of MUC181 11 706 9042.
a).
C-ND license.peptide fragments may alter during tumor progression (cancer cell
differentiation) [6].
It is clear that antibodies against such cancer-relevant MUC1 struc-
tures are promising candidates for the development of novel anti-
tumor drugs. One of the representative examples of the important
anti-MUC1 antibodies are monoclonal antibodies recognizing a peptide
epitope Pro-Asp-Thr-Arg (PDTR)motif on tandem repeat region [7–13].
The humanized mAb with fully human glycoforms has recently com-
pleted clinical phase I study andmoved to phase II clinical development
in ovarian cancer [11–13]. It is noteworthy that this mAbmore strongly
recognizes a glycosylated peptide epitope PDTR having Tn or T antigen
than naked peptide fragments while its binding proﬁle against this pep-
tide epitope with other glycoforms remains unclear. In 1998, a panel of
56 anti-MUC1 mAbs was investigated at the workshop of MUC1 [14].
The results of this assessment and the following studies [15] also indi-
cated that all antibodies had different binding speciﬁcities against
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with peptides involving DTR moiety. In addition, it was reported that
O-glycosylation at the threonine residue in PDTR motif led to enhance
binding afﬁnity with most antibodies [16–18]. However, it seems also
that glycan speciﬁcity ofmost anti-MUC1mAbs recognizing this peptide
region is not fully elucidated.
Extensive efforts have also been paid toward the development of the
MUC1-targeted cancer vaccines based on carrier-conjugated MUC1
fragments [19–29]. However, it is important to note that clinical out-
come of this approach might be strongly dependent on the binding
speciﬁcity of the antibody to combined glycopeptide epitopes raised
by immunization of MUC1 vaccines because cancer-associated antigens
are generated essentially by altered posttranslational glycosylation at
the individualO-glycosylation sites involved in the antigenic peptide se-
quences. It is well documented that various cancer cells often express
MUC1 bearing immature aberrant O-glycans such as Tn, T, and their
sialylated structures [30]. Therefore, immunization with MUC1-based
vaccines carrying such glycoforms appears to be a promising approach
to raise speciﬁc immune response against the pre-mature cancer cells,
while the epitopes of the antibodies raised by vaccinations, which in-
clude both the peptide backbone aswell as cancer-associated posttrans-
lational glycosylation, have been little discussed. In addition, it is of
emerging importance to proﬁle the individual's serum levels of autoan-
tibodies to cancer-relatedMUC1 fragments [31–33] because the autoan-
tibody signaturemay be compromised of an accumulation of antibodies
elaborated in the presence of pre-malignant cells at very early stages of
tumor development [34,35].
On the other hand, shedding of the MUC1 fragments from cancer
cells into the circulation in the bloodstream is also observed in many
cancer patients [36,37]. MUC1 antigens known as CA15-3, CA27.29,
CD227, EMA, PEM, or PUM with different properties between normal
and cancer cells have therefore been considered as promising bio-
markers [38]. CA15-3 is one of the potent diagnostic MUC1-based
serum markers known for an early recurrence of breast cancer [39]
and for evaluating the efﬁcacy of treatment for metastatic breast cancer
[40]. However, it is well known that CA15-3 is detected from patients'
serum not only in breast cancer but in many other adenocarcinoma
such as lung, pancreas, kidney, ovary, uterus, colon, and even in cases
for endometriosis, pelvic inﬂammatory diseases and hepatitis [41–43].
At present, circulating CA15-3 is detected by the sandwich assay using
two key mAbs, namely DF3 and 115D8. DF3 was generated against a
human breast carcinoma metastatic to liver [44], while 115D8 was
raised against human milk-fat globule membrane that should exhibit
a broad binding afﬁnity to most MUC1 fragments [14,45]. Though the
epitopes of DF3 appeared to locate at a TRPAPGS region in the tandem
repeat [46], its binding speciﬁcity and afﬁnity strength toward the pep-
tides having different glycoforms at the threonine residue is unknown.
This may indicate that glycans attached at this epitope inﬂuence greatly
to the speciﬁcity in the interaction between DF3 and circulating CA15-3
in sera of patients suffering from abovementioned various diseases,
leading to inaccurate conclusions. Krebs von den Lungen-6 (KL-6) is
also one of the clinically important MUC1-related antigens currently
used as a practical serum biomarker for diagnosing various lung dis-
eases associated with pneumonitis [47,48]. Anti-KL-6 mAb is a promis-
ing probe for detecting KL-6 in bloodstream and the minimal epitope
structure recognized by this mAb has recently been discovered by
our group to be heptapeptide PDTRPAP having sialyl T antigen
(Neu5Acα2,3Galβ1,3GalNAcα1→) at threonine residue [49]. Given
that anti-KL-6 mAb reacts with serum MUC1 in patients suffering
from lung adenocarcinoma, breast cancer, colorectal adenocarcinoma,
and hepatocellular carcinoma in addition to interstitial pneumonia
[50–54], it is obvious that elucidation of accurate glycopeptide epitope
for such mAbs is of emerging importance to reveal the false positive
cross-reactions due to “tolerance in the glycan recognition” [49].
Microarray displaying antigenic glycopeptides is an attractive and
powerful tool for high throughput screening of antibodies and itsepitope mapping analysis including glycan-binding proﬁles. Recently,
some pioneering studies [55,56] demonstrated the occurrence and clin-
ical potentials of serum autoantibodies against glycans [57–60], while
their exact speciﬁcities and functions seem still very elusive. On the
other hand, serum antibodies to combined glycan-peptide epitopes
are easier to deﬁne and more promising probes to react with disease-
relevant mucin glycopeptides [31–33]. However, it seems likely that
only a few are in current use for large-scale glycan/glycopeptide micro-
arrays intended for diverse applications [55,59,61]. We considered that
a much more efﬁcient and versatile method for the preparation of
MUC1-glycopeptides microarray would accelerate greatly a creation of
new class diagnostic and therapeutic anti-MUC1mAbswith a promising
clinical outcome. In the present study, we report a facile and standard-
ized protocol for the fabrication of high performance microarrays
displaying robust peptides/glycopeptides library on the basis of
“glycoblottingmethod”, a general protocol for the site-speciﬁc immobi-
lization of compounds with an aldehyde or an equivalent ketone func-
tional group under a mild aqueous condition without any coupling
reagent [62]. Advantage of our array format is demonstrated by highly
sensitive and quantitative proﬁling of anti-MUC1mAbs and IgG autoan-
tibody signature to MUC1 fragments in healthy human serum.
2. Experimental section
2.1. Materials
All commercially available solvents and reagents were used
without puriﬁcation. TentaGel S RAM resin was purchased from
Rapp Polymere GmbH (Tübingen, Germany), and Nα-Fmoc-amino
acid derivatives except for glycosylated compounds and recombinant
rat α2,3-(O)-sialyltransferase (α2,3-SiaT) were purchased from Merck
Millipore (Darmstadt, Germany). Nα-Fmoc-glycosylated amino acids
such as Fmoc-(Ac3GalNAcα)serine/threonine and Fmoc-(Ac4Galβ1,
3Ac2GalNAcα)serine/threoninewere synthesized according to themeth-
od reported previously [63,64]. 1-[Bis(dimethylamino)methyliumyl]-
1H-benzotriazole-3-oxide hexaﬂuorophosphate (HBTU), 1-hydroxy-
benzotriazole monohydrate (HOBt) and N,N-diisopropylethylamine
(DIEA) were purchased from Kokusan Chemical Co., Ltd (Tokyo, Japan).
N,N-Dimethylformamide (DMF) and 20% piperidine in DMF was pur-
chased from Watanabe Chemical Industries, Ltd. (Hiroshima, Japan).
Acetic anhydride and 2,2,2-triﬂuoroacetic acid (TFA) were from Wako
Pure Chemical Industries, Ltd. (Osaka, Japan). 5-Oxohexanoic acid was
from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Cytidine-5′-
monophospho-β-D-N-acetylneuraminic acid, disodium salt (CMP-
Neu5Ac) was from Yamasa Corporation (Chiba, Japan). Preparative
HPLC separations were performed using a Prominence Shimadzu High
Performance Liquid Chromatographs (HPLC) system equipped with
two LC-6AD pumps, an SPD-20A UV/VIS detector and Inertsil ODS-3
reversed-phase C18 column (250 × 20 mmI.D.). Puriﬁed compounds
were analyzed using a Waters Acquity Ultra Performance LC system
(see also, Supporting Information). High-resolution electrospray ioniza-
tion mass spectra (ESI-HRMS) using JEOL JMS-700TZ and amino acid
analyses using JEOL JLC/500 equipped with ninhydrin detection system
were performed in Center of Instrumental Analysis at HokkaidoUniversi-
ty.Monoclonal antibodies, VU-3D1,Ma552, VU-12E1, andVU-11E2,were
obtained from Sanbio B. V. (Uden, the Netherlands), SM3 mAb was from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), VU-3C6 mAb was
from Exalpha Biologicals, Inc. (Shirley, MA, USA), and DF3 mAb was
from Covance Research Products, Inc. (Emeryville, CA, USA). Anti-KL-6
mAb labeled with alkaline phosphatase from Lumipulse® KL-6 Eisai (a
reagent kit to determine KL-6 antigen) was purchased from Sanko
Junyaku Co., Ltd. (Tokyo, Japan). FluoroLink™ Cy™3-labeled goat anti-
mouse IgG (H + L) was from Amersham Biosciences (Buckinghamshire,
UK). Biotin–goat anti-human IgG (H + L) conjugates (ZyMax™ Grade)
were from Invitrogen Corporation (Carlsbad, CA, USA). Amersham
Cy™3-streptavidin and Amersham Cy™3 mono-reactive dye pack
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slides were basically manufactured by Sumitomo Bakelite Co., Ltd.
(Tokyo, Japan) as follows: Glass-like raw materials made of cyclic poly-
oleﬁn were molded into slides. The surface of naked slides were coated
by methacrylic polymer, (2-methacryloyloxyethylphosphorylcholine-
cyclohexylmethacrylate-N-[2-[2-[2-(t-butoxycarbonylaminooxyacetyl-
amino)ethoxy]ethoxy]ethyl]-methacrylamido copolymer (N-protected
AO/PC-copolymer) [65,66]. The size of a slide is 75-mm long, 25-mm
wide and 1-mm thick. Hybridization covers (60 × 25 × 0.7 mm) were
also obtained from Sumitomo Bakelite Co., Ltd. SIMplex 16 multi-array
systemwas from GenTel BioSciences, Inc. (Madison, WI, USA). “Reaction
buffer” that speciﬁed in the present study is a solution of 50 mM Tris–
HCl, 100 mM NaCl, 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2, 0.05%
Tween 20, pH 7.4. “Washing buffer” that speciﬁed in this paper is a solu-
tion of 50 mMTris–HCl, 100 mMNaCl, 1 mMCaCl2, 1 mMMnCl2, 1 mM
MgCl2, pH 7.4. Hybri Containerwas purchased fromGreiner-Bio-One Co.,
Ltd. (GmbH, Germany) for washing slides. Slides adapter CombiSlide®
was from Eppendorf Co., Ltd. (Hamburg, Germany) as a centrifugal sup-
port of slides for drying. AFM images were measured in the range of
500 × 500 nm with NanoScope (Digital Instruments, Santa Barbara,
CA, USA). Fluorescence images of microarray slides after assays were
measured at 10 μm resolution on a Typhoon Trio plus variablemode im-
ager (GE Healthcare) with a green (532 nm) laser and a 580 BP 30 ﬁlter
at a PMT voltage of 600 V and normal sensitivity. The digital images of
ﬂuorescence responseswere analyzed using ArrayVision™ software ver-
sion 8.0 (GEHealthcare) andwere graphed using GraphPad Prism 5 soft-
ware (San Diego, CA, USA).
2.2. General methods for the solid-phase synthesis of peptides and
glycopeptides
Peptides (1–41 and 51) and glycopeptides (42–47 and 52–57) were
synthesized by using an Apex 396 automated multiple peptide synthe-
sizer (AAPPTec, Louisville, KY, USA) in a general manner of solid-phase
peptide synthesis. TentaGel S RAM resin (100 mg each, loading
0.24 mmol g−1) was swollen with DMF for 1 h at ambient temperature
prior to use. Protective groups for masking side chain of Fmoc-amino
acids are selected as indicated below: tert-butyl for Ser, Thr and Asp;
trityl for His; and 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl
(Pbf) for Arg residue, respectively. As for the coupling reactions, Fmoc-
amino acids or Fmoc-glycosylated amino acids (5 equiv) were incorpo-
rated by use of HBTU (5 equiv), HOBt (5 equiv) and DIEA (10 equiv) in
DMF for 2 h at ambient temperature. For the capping at N-terminus, a
cocktail of acetic anhydride (4.75%, v/v), DIEA (2.25%, v/v), and HOBt
(1.99% w/v) in DMF was treated for 10 min at ambient temperature.
Fmoc group was removed by treating with 20% piperidine in DMF for
2 × 10 min at ambient temperature. The resin was washed at every
step with DMF for 2 min ﬁve times at ambient temperature. 5-
Oxohexanoic acid (5 equiv) was introduced to N-terminus of target
(glyco)peptidyl-resins according to the same coupling procedure at a
ﬁnal step. Cleavage of the product from resin and removal of acid-
labile protective groups were carried out concurrently by treating the
resin with 90% aqueous TFA for 2 h at ambient temperature. The solu-
tion was ﬁltered and concentrated by a ﬂow of nitrogen gas, and the
crude peptides or glycopeptides having O-acetylated glycan were pre-
cipitated using cold diethylether. Glycopeptides 42–47 and 52–57
were obtained by treating with alkaline condition (pH 12.4) in MeOH
for 1.5 h according to the previously reportedly [45,67–69]. Finally,
crude peptides and glycopeptides were puriﬁed by preparative HPLC.
High-resolution ESI-MS, UPLC chromatograms and amino acid analyses
of all compounds were described in Supporting Information.
2.3. Enzymatic sialylation of glycopeptides having T antigen
To the stock solutions of 8 mM glycopeptides (45–47 and 55–57) in
water were added 1 M HEPES-NaOH buffer (pH7.0), 1 M MnCl2,100 mM CMP-Neu5Ac, 1.4 U ml−1 α2,3-SiaT and Milli-Q water to ad-
just the ﬁnal concentration as follows: [49] 1 mM glycopeptide,
50 mM HEPES-NaOH buffer, 10 mM MnCl2, 5 mM CMP-Neu5Ac and
20 mU ml−1 α2,3-SiaT. After gently shaking for 24 h at ambient tem-
perature, the reaction mixture was subjected to the puriﬁcation by pre-
parative RP-HPLC to afford compounds 48–50 and 58–60. High-
resolution ESI-MS, UPLC chromatograms and amino acid analytical
data of all compounds were summarized in Supporting Information.
2.4. Preparation of glycopeptide microarray
Slides coated by N-protected AO/PC-copolymer were immersed in
2 M HCl for 4 h at 37 °C, and then washed twice with water and dried
by centrifugation (2000 rpm, 2 min, ambient temperature). Synthetic
peptides and glycopeptides were spotted on the slides prepared above
as follows: Quadruplicates of 5 mM 1–20 in 25 mM sodium acetate
(pH 5.0) with 0.00025% (w/v) Triton X-100 were spotted on BioChip
Arrayer (Filgen Inc., Aichi, Japan) with a 0.8-mm pitch using a Filgen
solid pin (400 μm pin diameter). Quadruplicates of 0.25 mM 21–40
or 0.25 mM 41–60 in 25 mM acetate buffer (pH 5.0) with 0.00025%
(w/v) Triton X-100 were spotted on OmniGrid® Micro (Digilab Inc.,
Marlborough, MA, USA) with a 0.8 mm pitch using four ChipMaker™
CMP6 micro spotting pins (200 μm spot diameter, ArrayIt Corporation,
Sunnyvale, CA, USA). The slides after spotting were placed in a dry
oven for 1 h at 80 °C to complete oxime bond formation according to
the general condition used in glycoblotting of various hemiacetals. Re-
cently, it was demonstrated that ketone-capped glycopeptides can be
immobilized quantitatively at room temperature as reported previously
[67]. After washing once with Milli-Q water, the slides were immersed
in an aqueous solution of 10 mg ml−1 succinic anhydride for 1 h at am-
bient temperature for capping free aminooxy groups remained on the
slide surface. The slides after washing twice with Milli-Q water were
dried by centrifugation (2000 rpm, 2 min, at ambient temperature)
and then used for further binding assay of anti-MUC1 mAbs. The dy-
namic range and the detection limit were investigated preliminarily
by means of anti-MUC1 mAb (VU3C6) as an example (Figures S1 and
S2 in the Supporting Information). Brieﬂy, it was indicated that the
binding of VU3C6 with an array prepared by spotting the solution of a
positiveMUC1 glycopeptide (1.0 mg ml−1) can bemonitored quantita-
tively by incubation with a ﬂuorophore-tagged secondary antibody
against this primary antibody at a range from 100−pg−ml−1 to
50 ng ml−1. Calculated from the concentration of stock solutions and
the performance of the spotting pins (~1.8 nl per spot), approximately
10−12–10−11 mol of peptides/glycopeptides could be immobilized.
2.5. Epitope mapping of anti-MUC1 mAbs using peptide/glycopeptide
microarray
Anti-MUC1 mAbs were diluted with reaction buffer to make
1 μg ml−1 mAb solutions. A hybridization covers were mounted on
the slides, and the dilutedmAb solutions (70 μl each) were carefully in-
fused through narrow gaps between slides and covers. After ﬁlling the
void with the solution, the slides allowed to remain for 2 h at ambient
temperature. The hybridization covers were removed and the slides
werewashedwithwashing buffer for 2 × 2 min, and then dried by cen-
trifugation (2000 rpm, 2 min, ambient temperature). Unused hybridi-
zation covers were mounted to the slides, and 1 μg ml−1 Cy™3-
labeled goat anti-mouse IgG antibody in reaction buffer (70 μl each)
was infused to ﬁll the void. After standing for 1 h at ambient tempera-
ture, the uncovered slides were washed with washing buffer for
2 × 2 min, followed by water for 1 × 1 min. The slides dried by centri-
fugation (2000 rpm, 2 min, ambient temperature) were subjected to
ﬂuorescent image scanning on a Typhoon Trio plus and the ﬂuorescent
responses were measured and analyzed using an ArrayVision software
as described in the above (see also, Figure S3 in the Supporting
information).
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fragments
This study was performed in accordance with the ethical standards
the World Medical Association Declaration of Helsinki and approved
by the institutional ethical committee of Faculty of Advanced Life
Science, Hokkaido University. Informed consent was obtained from all
serum donors. Human sera were collected from six healthy volunteers
(male n = 3, female n = 3, mean age 57.3 ± 7.3 years) after written
informed consent was acquired. Human sera (3 μl) were diluted with
reaction buffer (297 μl) and the solutions were subjected to centrifugal
ﬁltration (12,000 ×g, 3 min, 4 °C) with Amicon Ultrafree®-MC centrif-
ugal ﬁlter units (pore size 0.45 μm, Durapore PVDF membrane) that
purchased from Merck Millipore (Billerica, MA, USA). Duplicates of
5 mM 41–60 in 25 mM sodium acetate (pH 5.0) with 0.00025% (w/v)
Triton X-100 were spotted to the pretreated slides on BioChip Arrayer
with a 0.8-mm pitch using a Filgen solid pin (400 μm pin diameter).
Cy3mono-reactive dye (1 μg ml−1) that dissolved in the same spotting
buffer was also spotted on the same slides as grid markers. Washing,
capping and drying of the slideswere performed as the same procedure
described previously. After installing the slides to SIMplex™ 16 gaskets,
100 μl of human serum solution was applied to each well and the slides
were allowed to remain for 2 h at ambient temperature. After removal
of the solutions by aspiration, eachwell waswashedwithwashing buff-
er (100 μl) for 2 min three times and 0.1 μg ml−1 biotin-labeled goat
anti-human IgG conjugate in reaction buffer (100 μl) was next added.
After standing for 1 h at ambient temperature, each well was washed
as the same and Cy™3-labeled streptavidin in reaction buffer
(1.0 μg ml−1) was ﬁnally added. After standing for 1 h at ambient tem-
perature, the slides were washed as the same manner, and the slides
uninstalled gaskets were rinsed with Milli-Q water for 1 × 1 min. The
slides dried by centrifugation (2000 rpm, 2 min, ambient temperature)
were subjected to scan ofﬂuorescent images on a Typhoon Trio plus and
the ﬂuorescent responseswere analyzed using an ArrayVision software.
3. Result and discussion
3.1. A novel microarray platform to display robust synthetic peptides/
glycopeptides
The primary aim of the present studywas to establish a versatile and
highly sensitivemicroarray platform for the discovery and characteriza-
tion of antibodies reacting speciﬁcally with glycopeptides as disease rel-
evant epitopes. We set the criteria required for new class peptide/
glycopeptide microarray as follows: (i) A microarray slide having non-
fouling surface is made of a base material with more advantages than
a glass in disposability, safety, shape forming, and most importantly
low background noise, (ii) Covalent immobilization of multifunctional
peptides/glycopeptides can be achieved by a straightforward scheme
from the synthesis to the site-speciﬁc immobilization in a chemoselective,
spontaneous, and uniform fashion, and (iii) A standardized protocol
can be applied widely for the fabrication of microarrays carrying robust
compound libraries of not only peptides/glycopeptides but a variety
of glycoconjugates including free N/O-glycans, glycosphingolipids,
and glycosaminoglycans as potential candidates for disease speciﬁc
antigens.
Thesurfaceofaglass slidescaffoldused forprintingpeptides/glycopeptide
microarray is usually functionalized with N-hydroxysuccinimide (NHS)
esters in direct or polymer coating manner for immobilizing compounds
with amino group via amide bond formation [55,56]. However, this con-
ventional approach has disadvantage to react with peptides/glycopep-
tides on the surface in an undesired fashion due to the difﬁculty in the
site-speciﬁc coupling reaction of NHS ester with compounds bearing
multiple amino groups and other potentially reactive sites rather than
the targeted N-terminus [70]. Unfavorable tethering peptides/glycopep-
tides leads to possible misinterpretation in the speciﬁc interaction ofthe antibodies with a target antigen more severely rather than the cases
for the immobilization of macromolecular proteins. In addition, glass-
based surfaces involve the risk of cracks andbreaks during transportation,
use, and disposal cause of accidental injuries and subsequent infections,
which are not favorable features for the clinical applications. Although
NHS ester-activated slides have also been used extensively for the prepa-
ration of glycans [71] and glycosphingolipids microarray [72], prerequi-
site modiﬁcation of every carbohydrates to attach an amino-handle
is needed to print on this surface. On the solid-phased assay plat-
forms, non-speciﬁc adsorption of various abundant biomolecules in
human sera is one of the most serious and problematic phenomena
that leads to enhance background signals. Non-speciﬁc binding
may usually be minimized by saturating the unoccupied sites other
than immobilized compounds with blocking reagents such as bovine
serum albumin, skin milk, gelatin, and so on. These reagents, howev-
er, sometimes mask even compounds displayed and cause a signiﬁ-
cant decrease of the signals of interest. Consequently, it is likely
that the establishment of assay protocols becomes more cumber-
some and complicated due to optimization of blocking condition as
well as procedures for the immobilization of individual compounds
of interest. It was also reported that glass slides coated with func-
tionalized hydrogel [73] have been shown to give very little back-
ground in serum binding studies [71].
As a potential and alternative material, we selected a cyclic polyole-
ﬁn plastic with adequate properties of physical strength, optical trans-
parency, and low autoﬂuorescence as a base material of a microarray
slide. This plastic slide satisﬁes our requirement for disposal use and
safety manipulation, and it is easily moldable not only into slide format
but into other expansive formats such as ﬁlm, tube, and plate. Merit of
the use of such sophisticated plastic material is evident because the mi-
croarray technique could expand to the fabrication of microtiter plates,
microﬂuidic chips, and various types of diagnostic sensor devices. It was
hypothesized that integration of chemoselective ligation, notably
“glycoblotting method [62]” for capturing compounds involving a ke-
tone/aldehyde functional group, into the surface of such plastic material
would facilitate greatly to tether peptides/glycopeptides. We have pre-
viously reported the feasibility of aminooxy (AO)-functionalized poly-
acrylamide copolymer in a seamless chemical and enzymatic synthesis
of robust compound libraries of mucin glycopeptides [67,74,75]. Our
strategy allowed for rapid and high throughput synthesis of highly com-
plicated glycopeptides by connecting two different polymer platforms,
solid phase and water soluble supporting materials. It was demonstrat-
ed that peptides/glycopeptides can be captured quantitatively by AO-
functionalized polymers through an oxime-bond formation when the
N-terminus is capped by a reagent involving ketone/aldehyde auxiliary.
Advantage of glycoblotting method is clear because this reaction pro-
ceeds smoothly under a mild aqueous condition without any side
reactions. This method allowed for the conjugation with glycans/
oligosaccharides, glycopeptides and a variety of compounds library in
a site-speciﬁc manner, although the optimization is often needed for
ﬁxing the suited reaction time due to the reversible oxime bond forma-
tion [62,76–78].
On the other hand, it has also been documented that phos-
phorylcholinemoiety of phosphatidylcholine, one ofmajor components
of biomembrane lipids, gives an excellent non-fouling surface
when incorporated into the coating materials such as synthetic
polymers and alkanethiol derivatives [79,80]. Recently, we dem-
onstrated that combined use of an AO-terminated alkanethiol deriva-
tive, 11,11′-dithio bis[undec-11-yl 12-(aminooxyacetyl)amino hexa
(ethyleneglycol)], and a phosphorylcholine (PC) derivative, 11-
mercaptoundecylphosphorylcholine, provides quantum dots (QDs)
with novel functions for the chemical ligation of ketone-functionalized
compounds and the prevention of non-speciﬁc protein adsorption con-
currently [81,82]. It should be emphasized that non-fouling characteris-
tic of highly stable PC self-assembled monolayers-coated AO-QDs (AO/
PC-QDs) makes in vivo direct monitoring of glycan-speciﬁc interaction
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into the vein of mouse tail possible [81]. Taking all these observations
into account, we decided to synthesize a novel multifunctional
methacrylic polymer (N-protected AO/PC-copolymer) as a coating ma-
terial of cyclic polyoleﬁn molded into array slides. A general procedure
for the chemical and enzymatic synthesis (Fig. 1A) and site-speciﬁc im-
mobilization of peptides/glycopeptides (Fig. 1B)were outlined. The tert-
butoxycarbonyl (Boc) protecting groups of AO-functions of the surface
copolymer were easily removed by treatment with aqueous hydrochlo-
ric acid prior to use. Next, AO-functional groups of microarray wereFig. 1. A seamless scheme for the preparation of glycopeptide microarray platform.
(A) Schematic image for the synthesis of N-(5-oxohexanoyl)-MUC1 peptides and glyco-
peptides based on chemical and enzymatic approach. (B) A general protocol for
chemoselective immobilization of MUC1 peptides and glycopeptides on the basis of a
concept of “Glycoblotting method”. N-Protected AO/PC-copolymer coated on the base
material is treated with 2 M HCl at 37 °C for 4 h and allowed subsequently to couple
with N-(5-oxohexanoyl)-peptides/glycopeptides in 25 mM acetate buffer (pH 5.0) at
80 °C for 1 h.subjected directly to the selective reactions with peptides/glycopeptides
capped with 5-oxohexanoic acid without any side reactions even in the
presence of undesired peptides/glycopeptides or contaminated impuri-
ties lacking a reactive ketone auxiliary. After blocking the redundant
AO-functions by treating with succinic anhydride, microarray displaying
peptides/glycopeptides can be used for further analysis without any
other speciﬁc treatments. Although we employed 4 ﬁxed concentrations
(1.0, 2.5, and 5.0 mg mL−1) of peptides/glycopeptides at 80 °C for com-
plete imine-coupling reaction with aminooxy-groups of the microarray
(Supporting Information, Figure S1), the optimization might be needed
for improving the sensitivity or detection limit due to the difference of
the afﬁnity with monoclonal antibodies tested.
Needless to say that this protocol is feasible for the direct immobili-
zation of free glycans as demonstrated in the large-scale glycan analysis
[77,83–85]. Atomic force microscopy (AFM) demonstrated that coating
by methacrylic copolymer having PC moiety prevents perfectly the sur-
face of a polypropylene-based slides from non-speciﬁc protein adsorp-
tions (Fig. 2). No signiﬁcant adsorption of hydrophobic TGF-β, basic
histone H1, and glycoprotein hormone erythropoietin was detected on
the surface coated by the PC-copolymer while considerable accumula-
tion of all these proteins was observed on the naked plastic surface
when exposed to the protein solutions. However, it is still not clear
that the present plastic format is superior to other glass-based microar-
rays because no quantitative study using other available format has
been carried out.
3.2. Microarray displaying synthetic MUC1 peptides/glycopeptides
To validate the potentials of the present microarray format in the
precise epitope mapping analysis of anti-MUC1 mAbs, we designed a
compound library composed of 60 MUC1 peptides/glycopeptides,
which are generated by cutting MUC1 tandem repeat sequence into
overlapping fragment with equal length (Table 1).
The library can be divided into three categories of 10-mer (1–20),
15-mer (21–40), and 23-mer (41–60) in size. MUC1 peptides (1–40)
are non-glycosylated peptides with one amino acid residue shifted be-
tween two proximate fragments. On the other hand, 23-mer MUC1
fragments (41–60) were designed by focusing on the glycoforms at
ﬁve potentialO-glycosylation sites and its distribution in the two differ-
ent tandem repeating units involving three extra amino acid residues
that can be regarded as a part of neighboring repeating unit. To assess
the effect on the antibody bindings caused by altering cleavage sites in
the MUC1 tandem repeating sequence, we assigned two sequentially-
identical peptide fragments with two different N-terminus starting
from GVT (41–50; fragment I) and STA (51–60; fragment II) motifs.
MUC1-peptide/glycopeptide library was constructed by a general
procedure indicated in Fig. 1A on TentaGel resin with RinkAmide linker
using Fmoc solid-phase peptide synthesis protocol on a standard
peptide synthesizer. With respect to O-glycan modiﬁcation, three
tumor-associated O-glycans of Tn (GalNAcα1→), T (or TF; Galβ1,
3GalNAcα1→), and sialyl-T (Neu5Acα2,3Galβ1,3GalNAcα1→) were
singly linked to one of the ﬁve serine/threonine resides that are poten-
tial sites to be O-glycosylated in a tandem repeat unit. All peptides/
glycopeptides were terminated by capping with a 5-oxohexanoyl
group at N-terminal end and a carboxamide group at C-terminal end
of the sequence. All compounds (1–60) were employed for the site-
speciﬁc immobilization by a standardized protocol indicated in Fig. 1B.
3.3. Accurate epitope mapping of anti-MUC1 mAbs
To test the performance of our newly established microarray format
displaying peptides (1–41, and 51) and glycopeptides (42–50, and 52–
60), the epitope mapping analysis of a panel of eight commercially
available anti-MUC1 mAbs listed in Table 2 was carried out. Judging
from clear ﬂuorescence images illuminated by secondary antibody
(Cy3-labeled goat anti-mouse IgG antibody) shown in Fig. 3 (see also,
Fig. 2. AFM views of non-speciﬁc protein adsorption to a base plastic material (naked polypropylene slides) (A) and the surface after coating with PC-methacrylic copolymer (B). Silds were
exposed to purewater (1; negative control), or 10 nMaqueous solutions of TGF-β (2; a hydrophobic protein), histoneH1 (3; a basic protein), and erythropoietin (4; a glycoprotein hormone)
as typical model proteins. After incubating with the solution for 1 h at 37 °C, the slides were washed three times with 0.05% (w/v) Tween 20 in deionized water and then air-dried.
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criteria required for accurate determination of the essential epitopes of
antibodies with high sensitivity and reproducibility. It was revealed
that 6 antibodies (VU-3D1, VU-12E1, Ma552, VU-3C6, SM3, and DF3)
have a quite similar binding proﬁle towards the naked MUC1 peptides
(1–40). As anticipated, no remarkable response with these naked
MUC1 peptides was observed in case of anti-KL-6 mAb [49]. Epitopes
identiﬁed as overlapping sequences of positive peptides were summa-
rized in Table 3, inwhich values equal to ormore than 20% relative inten-
sity of a maximum signal arbitrarily were deﬁned for elucidating
dominant peptide epitopes of mAbs. The peptide epitopes with
immunodominant PDTR motif concluded by the present microarray
were largely consistent with those reported previously using different
assay platforms [11,15]. Importantly, differences in the results of
10-mer from 15-mer microarray suggested that the location of the
C-terminal proline residue included in the DTRPAP motif in the MUC1
fragments inﬂuence signiﬁcantly the binding afﬁnity with VU-3D1,
VU-12E1, Ma552, VU-3C6, and DF3. More clearly, VU-11E2 showed
much higher afﬁnity with peptides carrying DTRP motif when the pro-
line residue is placed at C-terminal end [2,22] than peptides 1 and 2, in
which C-terminal endsweremodiﬁedwith alanine residue. It should be
emphasized that non-fouling nature of themicroarray allowed for such
highly sensitive detection and differentiation of the binding proﬁles
based on relatively weak and broad afﬁnity of these mAbs with naked
MUC1 peptide fragments immobilized on the solid-plastic surface.
However, it is important to note that the density of the immobilized
peptides/glycopeptides signiﬁcantly might inﬂuence the sensitivity in
the detection, in which the density can be controlled by the printing
concentration of peptide (Figure S1–3). Especially, there seemed to be
a need of relatively high printing concentration as indicated in case
for the analysis of short 10-mer peptides exhibiting lower afﬁnity
with most antibodies when compared with those of glycopeptides. In
addition, both N- and C-terminal amino acids in the short peptides
may affect the interaction with antibody even when the peptide con-
tains the minimal epitope region, suggesting that mapping analysis
using robust compound library of various fragments containing the pro-
posed epitope would become a promising approach to identify an es-
sential epitope structure against the target antibody.
Next, our attention was directed to the effect of O-glycosylation
at the immunodominant PDTRP motif on the interaction of mAbs
with MUC1 fragments. In the present study, modiﬁcations of two 23-
mer peptides with Tn, T, and sialyl-T antigens were performed at
ﬁve potential glycosylation sites, PDTRP [42,45,48,54,57,60], GSTA
[43,44,46,47,49,50], and VTSA [52,53,55,56,58,59], respectively. Micro-
array slides displaying compounds 41–60 were prepared by astandardized protocol illustrated in Fig. 1B and employed for assessing
the binding proﬁle of mAbs. Naked MUC1 peptides 41 and 51 were
not recognized by all mAbs tested because a key proline residue of
the DTRP region is far from the C-terminus as indicated by the results
of 10-mer and 15-mer peptides (Fig. 3). However, seven mAbs
except anti-KL-6 mAb exhibited distinctly enhanced afﬁnities with
peptides glycosylated at DTRP motif [42,45,48,54,57,60] while any O-
glycosylation at other sites (GSTA and VTSA) did not affect their binding
proﬁle at all. This result clearly indicates that the glycosylation at
the threonine residue is essential for converting the PDTRP motif into
an immunodominant epitope within the macromolecular MUC1 tan-
dem repeats, even though these mAbs did not show any glycoform
speciﬁcity. It was also reported by using conventional ELISA assay
format that attachment of GalNAc residue at the DTR motif improved
binding to anti-MUC1 mAbs involving VU-3D1, VU-12E1, VU-11E2,
Ma552, VU-3C6, and SM3 [14,86]. It is well documented that α-O-
glycosylation at Thr residues by GalNAc forces the peptide backbone
into a stable extended conformation, whichminimizes the steric effects
by further modiﬁcations yielding bulky branched O-glycan chains
[87–91] and serves as the preferred peptide conformations seen in
cancer-relevant peptide epitopes recognized by many anti-MUC1
mAbs [19–21,92].
On the contrary, it was demonstrated that the binding speciﬁcity of
anti-KL-6 mAb with peptides 48 and 60 (PDTRP motif bearing sialyl-T
antigen) is remarkable among 8 mAbs tested herein. The present re-
sults were in good agreement with our previous study identifying an
essential MUC1 epitope of anti-KL-6 mAb, PDT(sialyl-T)RPAP [49].
Interestingly, it seemed that the binding proﬁles of 7 mAbs (VU-3D1,
VU-12E1, VU-11E2,Ma552, VU-3C6, SM3, and DF3)with positive glyco-
peptides [42,45,48,54,57,60] are obviously different between fragments
I and II (Fig. 4). Although all thesemAbs showed a similar level of afﬁn-
ity bothwith fragments I and II carrying Tn antigen [42,54], afﬁnitywith
peptides bearing T and sialyl-T antigen [45,48,57,60] was strongly inﬂu-
enced by the location of PDTRP motif in these designated MUC1 frag-
ments. Considering the occurrence of the site-speciﬁc conformational
alteration during the glycosylation at this important epitope region
[91], it seems that such conformational impact by glycosylationmay de-
pend on the size of the fragment and the location of the epitope region
as well as the glycoform. However, it should be emphasized that anti-
KL-6 mAb did not show any changes in the binding proﬁle between
the two fragments. In other words, this result clearly indicates
that the distal sialylation of T antigen attached to PDTRPAP is a crucial
step to provide this peptide sequence with an essential combined-
glycopeptide epitope of anti-KL-6mAb through the site-speciﬁc confor-
mational alteration [91].
Table 1
Peptides and glycopeptides used in this study.
Each compound has a 5-oxohexanoyl group at N-terminus and an amide group at C-terminus. Shown in white letters highlighted in black are amino acids that are modiﬁed with tumor-
associated O-linked carbohydrate antigens speciﬁed in the table.
Entry Entry Entry Glycan
1 V T S A P D T R P A 21 P P A H G V T S A P D T R P A 41 G V T S A P D T R P A P G S T A P P A H G V T
2 G V T S A P D T R P 22 A P P A H G V T S A P D T R P 42 G V T S A P D T R P A P G S T A P P A H G V T Tn
3 H G V T S A P D T R 23 T A P P A H G V T S A P D T R 43 G V T S A P D T R P A P G S T A P P A H G V T Tn
4 A H G V T S A P D T 24 S T A P P A H G V T S A P D T 44 G V T S A P D T R P A P G S T A P P A H G V T Tn
5 P A H G V T S A P D 25 G S T A P P A H G V T S A P D 45 G V T S A P D T R P A P G S T A P P A H G V T T
6 P P A H G V T S A P 26 P G S T A P P A H G V T S A P 46 G V T S A P D T R P A P G S T A P P A H G V T T
7 A P P A H G V T S A 27 A P G S T A P P A H G V T S A 47 G V T S A P D T R P A P G S T A P P A H G V T T
8 T A P P A H G V T S 28 P A P G S T A P P A H G V T S 48 G V T S A P D T R P A P G S T A P P A H G V T Sialyl-T
9 S T A P P A H G V T 29 R P A P G S T A P P A H G V T 49 G V T S A P D T R P A P G S T A P P A H G V T Sialyl-T
10 G S T A P P A H G V 30 T R P A P G S T A P P A H G V 50 G V T S A P D T R P A P G S T A P P A H G V T Sialyl-T
11 P G S T A P P A H G 31 D T R P A P G S T A P P A H G 51 S T A P P A H G V T S A P D T R P A P G S T A
12 A P G S T A P P A H 32 P D T R P A P G S T A P P A H 52 S T A P P A H G V T S A P D T R P A P G S T A Tn
13 P A P G S T A P P A 33 A P D T R P A P G S T A P P A 53 S T A P P A H G V T S A P D T R P A P G S T A Tn
14 R P A P G S T A P P 34 S A P D T R P A P G S T A P P 54 S T A P P A H G V T S A P D T R P A P G S T A Tn
15 T R P A P G S T A P 35 T S A P D T R P A P G S T A P 55 S T A P P A H G V T S A P D T R P A P G S T A T
16 D T R P A P G S T A 36 V T S A P D T R P A P G S T A 56 S T A P P A H G V T S A P D T R P A P G S T A T
17 P D T R P A P G S T 37 G V T S A P D T R P A P G S T 57 S T A P P A H G V T S A P D T R P A P G S T A T
18 A P D T R P A P G S 38 H G V T S A P D T R P A P G S 58 S T A P P A H G V T S A P D T R P A P G S T A Sialyl-T
19 S A P D T R P A P G 39 A H G V T S A P D T R P A P G 59 S T A P P A H G V T S A P D T R P A P G S T A Sialyl-T
20 T S A P D T R P A P 40 P A H G V T S A P D T R P A P 60 S T A P P A H G V T S A P D T R P A P G S T A Sialyl-T
Sequence (N→C) Sequence (N→C) Sequence (N→C)
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sera
Autoantibodies against autologous tumor-associated antigens are
known to be detected in the asymptomatic stage of cancer and can
thus serve as highly sensitive biomarkers for early cancer diagnosis
[34,35]. Recent pioneering works that uncovered the occurrence of
human serum autoantibodies to glycopeptides in various cancer
patients [31,33,61] greatly motivated us to test our glycopeptide micro-
array for highly sensitive and selective detection of anti-MUC1 autoan-
tibodies in the circulating bloodstream. It is considered that the
repertoire of autoantibodies to MUC1 fragments is a molecular “ﬁnger-
print” of antibodies produced by the dynamic interplay between host's
individual immune system and pre-cancerous/cancer cells and may
hold promise in detecting early stages malignant processes [93]. Given
that the immunosurveillance by such anti-cancer autoantibodies
can identify and destroy cancer precursor cells in most healthy
cases [94–96], it is not surprising that we can observe signiﬁcant differ-
ences in the serum level of such autoantibodies even in cases for healthy
human controls. In fact, it can be seen that a few serum samples from
healthy controls also showed IgG autoantibodies to some MUC1 pep-
tides with Tn- or T-antigens, whereas the serum levels were apparently
lower than those detected in sera from patients with breast, ovarian,
and prostate cancer [31,33]. We hypothesized that autoantibody signa-
ture to cancer-relevant MUC1 glycopeptides in the serum of “normal”Table 2
Anti-MUC1 monoclonal antibodies used in this study.
Clone Isotype Immunogen
VU-3D1 IgG1 ZR-75-1 breast cancer cell line
VU-12E1 IgG1 ZR-75-1 breast cancer cell line
VU-11E2 IgG1 ZR-75-1 breast cancer cell line
Ma552 IgG1 ZR-75-1 breast cancer cell line
VU-3C6 IgG1 ZR-75-1 breast cancer cell line
SM3 IgG1 Deglycosylated puriﬁed milk mucin
DF3 IgG1 Membrane enriched fractions of human
metastatic breast carcinoma
KL-6 IgG1 Human lung adenocarcinoma-derived
cell line (VMRC-LCR)individuals is fundamental to assess dynamic immune response to
pre-cancerous cells. Small populations of pre-malignant cells expressing
MUC1 displaying aberrant O-glycans that generate IgG autoantibodies
may not proceed to malignancy at very early stages of tumor develop-
ment, and are hence eliminated. The immune response to a tumor as
it progresses from early to late stage might be updated and renewed,
and result in autoantibodies against progressively more cancer domi-
nant MUC1 epitopes. It is likely that lack or defect of the host immune
system to eliminate pre-malignant cells would lead to malignancy at
later stage. Therefore, it seems that the late stage anti-MUC1 autoanti-
body proﬁle could be comprised of an accumulation of antibodies gen-
erated at the earlier stages. Our interest was focused on the feasibility
of our microarray format in the quantitative analysis of anti-MUC1 IgG
autoantibodies in the healthy human sera.
As a preliminary pilot study, human sera collected from six healthy
volunteers (male n = 3, female n = 3)were incubatedwithMUC1mi-
croarray displaying compounds 41–60 at 100-fold dilutions. The levels
of IgG autoantibodies were monitored by probing with biotin-labeled
goat anti-human IgG and Cy™3-labled streptavidin. As anticipated, the
result clearly indicated that sera from 6 healthy individuals have signif-
icant levels of IgG autoantibodies to various MUC1 fragments carrying
Tn, T, and sialyl-T antigens, which showed apparent preference for the
peptide sequence (Fig. 5). Surprisingly, our array format elicited for
the ﬁrst time the signiﬁcant level of IgG autoantibodies recognizing
MUC1 fragments bearing sialyl-T antigen (sialylated core 1) in healthy
human sera. The levels of IgG autoantibodies to MUC1 peptides with
sialyl-T antigen were found to be higher than those to peptides with
other glycoforms and 6 out of 6 healthy individuals had IgG autoanti-
bodies to MUC1 glycopeptides 50 (GSTA), 59 (VTSA), and 60 (PDTR)
bearing this trisaccharide antigen (Fig. 5B). The IgG autoantibody
reacting with glycopeptide 60 shares the minimal epitope structure
for anti-KL6 mAb, clinically important biomarker for diagnosing inter-
stitial pneumonia [47,48]. More strikingly, it should be noted that high
level KL-6 can be often detected by thismAb in sera from various cancer
patients due to lower level autoantibody toMUC1 fragments containing
an epitope structure shared with anti-KL-6 mAb [50–54]. In other
words, circulating IgG autoantibody in normal human sera reacting
with this unique epitope may have an essential role for identifying cel-
lular malignancy and preventing disease progression. However, 5 out of
Fig. 3. Epitope mapping analysis of anti-MUC1 mAbs. Fluorescent responses of anti-MUC1 monoclonal antibodies against 10-mer peptides (top), 15-mer peptides (mddle), and 23-mer
peptides/glycopeptides. Each column represents the averageﬂuorescence intensity detected in four spots including standard deviation (see also, Figure S3). An ideal concentration of pep-
tides/glycopeptides for the immobilization, the dynamic range and the detection limit of IgG (100 pg ml−1 – 50 ng ml−1) were investigated bymeans of anti-MUC1mAb (VU3C6) as an
example (Figures S1 and S2).
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Table 3
Comparison of peptide epitopes for anti-MUC1mAbs revealed in this study and the results
reported in TD-4 workshop.
Clone Peptide epitope









The peptides corresponding to the positive spots with equal to or more than 20% relative
intensities of the spotwithmaximal intensity detected in individualmicroarraywere used
for identifying overlapped epitope sequences.
(a)Data reported by Price et al. [14] 7-mer (underline), 9-mer (bold), and 20-mer (plain)
peptides were respectively used to epitope mapping using different assay procedures by
three different groups.
(b)10-mer results shown in bold type; 15-mer results shown in plain type; overlapped se-
quences of both results shown underlined.
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bodies to 49 (GSTA) and 58 (VTSA) involving sialyl-T antigen, suggest-
ing that the antibody might have an anti-carbohydrate reactivity
rather than against “glycopeptides”. It was also revealed that only 2–4
out of 6 donors had IgG autoantibodies to MUC1 glycopeptides having
Tn or T antigen [42–46,53] as well as naked MUC1 peptides 41 or 51.
There might be a considerable difference in the serum levels of the
MUC1 autoantibodies between healthy human subjects. These results in-
dicate signiﬁcantly that the immune response to cancer-related MUC1
fragments might be ampliﬁed, edited and accumulated during the indi-
vidual immune surveillance processes in the presence of pre-malignant
cells at very early stages of tumor development. This may be a reason
why some patients develop these anti-MUC1 autoantibodies while
others do not, although further investigation using large number of
serum samples of health volunteers is necessary to test this hypothesis.
High levels of IgG autoantibodies to someMUC1glycopeptides in the
sera of various cancer patients may become potential biomarkers for
early detection of cancer [31–33]. However, it is considered that autoan-
tibody signature of the cancer patients is a result of an accumulation of
anti-MUC1 autoantibodies generated at the earlier stages and the serum
level of such IgG autoantibodies may also be inﬂuenced by the individ-
ual depending on whether their immune system is compromised
through many factors such as genetic background, other diseases,
stress-associated factors, and immunosuppression [97]. On the other
hand, it was also reported that high levels of a subset of IgG autoanti-
bodies to MUC1 glycopeptides in early stage breast cancer patients are
associated signiﬁcantly with reduced incidence and increased time toFig. 4. The effect of microenvironment of the DTRmotif on the binding afﬁnity and glycan
speciﬁcity of anti-MUC1 mAbs. A stacked bar graph summarizes relative glycan-binding
speciﬁcities for 23-mer glycopeptides carrying three different O-glycans (Tn, T, and
sialyl-T) at Thr [8] of fragment I [42,45,48] and Thr [15] of fragment II [54,57,60],
respectively.metastasis [31]. This exciting ﬁnding suggests that such anti-MUC1 au-
toantibodies may have a crucial function in the identiﬁcation and inhi-
bition of cancer progression.
Importantly, theﬁnding of a difference in the serumautoantibody sig-
nature of healthy volunteers was achievable bymeans of the present mi-
croarray format that can reduce background noise caused by non-speciﬁc
protein adsorption. This allowed for highly sensitive and accurate detec-
tion of the ampliﬁed interaction between low level serum autoantibodies
and densely clustered MUC1 glycopeptides depending on the strict
glycoform difference at the individual glycosylation sites. Judging from
the dynamic range of the array estimated by using VU3C6 (SI, Figures
S1 and S2), the levels of above IgG autoantibodies circulating sera ap-
peared to be in a range from 100 pg/ml to 50 ng/ml (0.67 pM–335 pM).4. Conclusion
We established a standardized method for the preparation of new
class microarray platform that allows highly sensitive and accurate
characterization of IgG antibodies to MUC1 peptides/glycopeptides.
The cyclic polyoleﬁn plastic slides functionalized with a coating copoly-
mer having reactive aminooxy- and biocompatible phospholipid-like
groups enabled not only chemoselective and spontaneous tethering of
compounds carrying a ketone/aldehyde group through an oxime bond
formation but minimizing background noise caused by non-speciﬁc
protein adsorption. Advantage of this array format was demonstrated
by rapid and precise epitope mapping analysis of seven anti-MUC1
mAbs among mAbs tested, in which anti-KL-6 mAb showed the highest
binding speciﬁcity toward the combination glycopeptide epitope carry-
ing sialyl T antigen (Neu5Acα2,3Galα1,3GalNAcα1→) at Pro-Asp-Thr-
Arg motif. On the contrary, other six anti-MUC1 mAbs could not dis-
criminate the modiﬁcation with three cancer related carbohydrate
antigens such as Tn, T, and sialyl T at thismotif while the binding afﬁnity
with the peptide epitope was enhanced signiﬁcantly by the glycosyla-
tion at this region. It should be emphasized that this assay permitted
highly sensitive detection of serum IgG autoantibodies to MUC1 glyco-
peptides at a wide dynamic range from 100 pg ml−1 to 50 ng ml−1
(0.67 pM–335 pM). The present microarray uncovered for the ﬁrst
time the occurrence of IgG autoantibodies to theMUC1 fragments carry-
ing sialyl T-antigen at ﬁve potential O-glycosylation sites in the healthy
human sera at 100-fold dilutions. Intriguingly, the array also showed
the signiﬁcant level circulation of IgG autoantibody to MUC1 fragments
having T antigen at PDTR motif, although antibody toward other MUC1
epitopes with T antigen at a different glycosylation site was not detect-
ed. However, the presentmicroarray slides do not coverMUC1 peptides
with sialyl-Tn [92,98] and a variety of O-glycoforms involved in core 2
[49], core 3 [31–33], and core 6 series having other important roles in
the regulation of cancer cell differentiation [99]. It is noteworthy that
human breast carcinoma cell lines MCF-7 and ZR75-1 produce domi-
nantly MUC1 with core 2-based O-glycans (83% in MCF-7 and 75% in
ZR75-1, respectively), while T47D expresses endogenousMUC1 bearing
core 1-based sialyl T antigen as one of its major glycoforms (45.9%)
[100,101].
Merit of the present peptides/glycopeptides microarray platform is
evident because the autoantibody signature may be a potent biomarker
both for early diagnosis ofmalignancy and cancer vaccine development,
while the levels of serum IgG autoantibodies to cancer relevant glyco-
peptide epitopes seem to depend strongly on the individual's immune
response generated during the intricate immunosurveillance processes.
To scrutinize the difference in the serum levels of autoantibodies to
combining glycopeptide epitopes as highly potential biomarkers, ad-
vent of high performance array format has been strongly needed. The
present straightforward strategywould greatly accelerate the discovery
research of new class autoantibodies aswell as the development of ther-
apeutic mAbs reacting speciﬁcally with disease-relevant glycopeptide
epitopes [102].
Fig. 5. IgG autoantibody signature revealed by glycopeptide microarray. (A) Fluorescent scanner images in gray scale-coloration of binding assays of six human sera specimens
using 23-mer (glyco)peptide microarrays. (B) Layout of the compounds (The seven spots with strong ﬂuorescence at center in each well are grid markers corresponding to Cy3
mono-functional dye). (C) A stacked bar graph of 6 healthy human sera. The results were represented as the mean of the ﬂuorescent response from duplicate determinations of
two independent experiments. The blue and red bars indicate the response from male and female sera, respectively.
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